Adma Biologics Inc (ADMA) financials
Adma Biologics revenue and earnings by year
Adma Biologics's revenue was $510 million in the fiscal year to December 31, 2025, up 19.6% from the year before. Net income was $147 million, 28.8% of revenue. Since the fiscal year to December 31, 2016, revenue has grown 53.7% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 10 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 510 | 426 | 258 | 154 | 81 | 42 | 29 | 17 | 23 | 11 |
| Revenue growth | 19.6% | 65.2% | 67.6% | 90.4% | 91.7% | 43.9% | 72.8% | -25.4% | 113.5% | — |
| Gross profit | 293 | 220 | 89 | 35 | 1 | -19 | -10 | -25 | -6 | 4 |
| Gross margin | 57.4% | 51.5% | 34.4% | 22.9% | 1.4% | -45.2% | -34.6% | -148.4% | -28.1% | 40.3% |
| Operating income | 191 | 139 | 22 | -39 | -58 | -65 | -41 | -60 | -39 | -17 |
| Operating margin | 37.5% | 32.6% | 8.4% | -25.5% | -72.1% | -153.8% | -141.1% | -354.9% | -172.7% | -162.6% |
| Net income | 147 | 198 | -28 | -66 | -72 | -76 | -48 | -66 | -44 | -20 |
| Net margin | 28.8% | 46.4% | -10.9% | -42.8% | -88.5% | -179.4% | -164.5% | -387.1% | -192.3% | -183.1% |
| Diluted EPS | $0.60 | $0.81 | -$0.13 | -$0.33 | -$0.51 | -$0.88 | -$0.89 | -$1.46 | -$1.89 | -$1.62 |
| Free cash flow | 28 | 110 | 4 | -73 | -126 | -115 | -80 | -65 | -40 | -18 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open ADMA in Markets.
How Adma Biologics makes money
Revenue by segment in the quarter to June 30, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| ADMA Bio Manufacturing | $124M | 99.4% |
| Plasma Collection Centers | $723K | 0.6% |
See also: ADMA valuation and P/E history · ADMA returns
No forecast, no recommendation. This page describes Adma Biologics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.